Vicplas International, a company engaged in the medical devices, and pipes and pipe fittings businesses, has reported a growth in revenue for FY2025 ended July 31, by 13.1% y-oy.
Revenue grew to $115.8 million due to higher revenue from its medical devices segment.
However, for the full year, the group reported a higher loss after tax of $2.4 million compared to the $1.4 million loss reported in FY2024.
This is mainly due to the lower positive results of the pipes and pipe fittings segment and higher finance costs.
The group says that this loss was mitigated by the improved results of the medical devices segment, albeit the negative result.
Revenue for the medical devices segment was $77.2 million in FY2025, a 22.3% y-o-y increase due mainly to an increase in orders following adjustments made over the course of the last two financial years by certain customers in their post-pandemic inventory holdings.
Meanwhile, revenue for the pipes and pipe fittings segment saw a decrease by 1.7% y-o-y to $38.6 million in FY2025 due to the segment’s approach in balancing sales against credit risk exposure, and adjusted selling prices to reflect lower raw material costs.
Raw materials and consumable increased 8.9% y-o-y to $4.7 million due to increase in production activities in the medical devices segment.
Other operating expenses increased 24% y-o-y to $19 million due to higher production activities.
See also: FJ Benjamin FY2025 red ink widens to $16.6 million
Overall, the group recorded a loss before tax of $1.7 million for the FY2025, and a loss after tax of $2.4 million.
Shares in Vicplas International closed 0.5 cents lower or 5.882% down at 8 cents on Sept 26.
